Chatain et al. utilized a tetracycline-inducible p210 BCR::ABL1 transgenic mouse model and demonstrated the efficacy of asciminib for Ph-positive acute lymphoblastic leukemia or CML-BP [9]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.